Clinical trial
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
NCT02330965
Study timeline
Study start (unknown)2014-12-01Date precision: month
Registry last updated2020-11-09
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Secondary Progressive Multiple Sclerosisunresolved
Interventions
Blood DrawPROCEDURE
Sponsors & collaborators
Autoimmunity Centers of Excellencecollaborator
Novartis Pharmaceuticalscollaborator
Mapped research locations
Los AngelesCalifornia, United States1SeattleWashington, United States1ClevelandOhio, United States1PortlandOregon, United States1AuroraColorado, United States1DetroitMichigan, United States1Ann ArborMichigan, United States1CharlotteNorth Carolina, United States1SacramentoCalifornia, United States1AlbuquerqueNew Mexico, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02330965 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.